Atropine Infusion Preparation and Administration
Preparation of Atropine Infusion
Atropine infusion can be prepared by diluting commercially available atropine (0.4 mg/mL or 1 mg/mL) in 0.9% sodium chloride, or by fortifying existing injectable atropine with pharmaceutical-grade atropine powder to achieve higher concentrations up to 2 mg/mL. 1, 2
Standard Preparation Methods
Commercial formulations: Atropine sulfate is available as 0.4 mg/mL or 1 mg/mL in single-dose vials, supplied as a sterile, nonpyrogenic isotonic solution with sodium chloride. 1
High-concentration preparation: For mass casualty scenarios or when large doses are needed, existing injectable atropine can be fortified with bulk pharmaceutical-grade atropine powder to create a 2 mg/mL concentration, which facilitates intramuscular administration and reduces volume requirements. 2
Extemporaneous compounding: A 1 mg/mL atropine solution can be prepared in 0.9% sodium chloride from sterile pharmaceutical-grade powder, requiring approximately 1 hour to complete once materials are available. 2, 3
Stability Considerations
Storage temperature: Atropine should be stored at 20°C to 25°C (68°F to 77°F), with excursions permitted to 15°C and 30°C. 1
Compounded solution stability: Atropine sulfate 1 mg/mL in 0.9% sodium chloride maintains stability for at least 72 hours at refrigeration (4°C to 8°C), room temperature (20°C to 25°C), and body temperature (32°C to 36°C), with concentrations remaining 95-103% of initial values. 3
Light protection: Solutions should be protected from light using amber occlusive covers to minimize photodegradation. 3
Refrigerated storage: Compounded products maintain potency for at least 8 weeks at refrigeration temperature and 4 weeks at room temperature. 2
Administration Protocol for Organophosphate Poisoning
In acute organophosphate poisoning, atropine must be administered immediately with an initial dose that is doubled every 5 minutes until full atropinization is achieved, followed by continuous infusion to maintain therapeutic endpoints. 4
Initial Dosing Strategy
Immediate administration: Give atropine without delay for severe manifestations including bronchospasm, bronchorrhea, seizures, or significant bradycardia (Class I, Level A). 4
Aggressive titration: Start with an initial dose and double it every 5 minutes—doses required are markedly higher than for routine bradycardia treatment. 4
Route of administration: Intravenous administration is preferred, though intramuscular delivery of higher-concentration formulations (2 mg/mL) is faster and easier in resource-limited mass casualty settings. 2
Endpoints of Atropinization
Atropinization is achieved when three specific clinical endpoints are met: clear lung fields on auscultation, heart rate greater than 80 beats/min, and systolic blood pressure greater than 80 mm Hg. 4
These endpoints must be sustained through continuous infusion rather than intermittent boluses. 4
Continuous micropump infusion achieves atropinization faster, requires lower total atropine doses, and results in lower mortality compared to repeated-bolus dosing. 5
Critical Limitations
Muscarinic effects only: Atropine antagonizes only muscarinic receptor overstimulation and does not reverse nicotinic paralysis or neuromuscular junction effects (Class I, Level C). 4
Mechanism of action: Atropine competitively antagonizes acetylcholine at muscarinic receptors on structures innervated by postganglionic cholinergic nerves, including exocrine glands and smooth and cardiac muscle. 1
Pharmacodynamic delay: Maximum effects on heart rate and saliva flow are delayed by 7-8 minutes after intravenous administration. 1
Aging of Acetylcholinesterase
Aging refers to the irreversible chemical modification of organophosphate-inhibited acetylcholinesterase that occurs over time, rendering the enzyme permanently inactivated and resistant to reactivation by oximes. 4
Mechanism and Clinical Significance
Biochemical process: After organophosphates bind to acetylcholinesterase, the enzyme-inhibitor complex undergoes a time-dependent dealkylation reaction that stabilizes the bond, making it irreversible. 4, 6
Critical timing window: Oximes (pralidoxime) must be administered early, before aging occurs, to successfully reactivate acetylcholinesterase (Class IIa, Level A). 4
Stereospecificity: The rate of aging varies depending on the specific organophosphate and stereoisomer involved—bioactivated profenofos-inhibited acetylcholinesterase demonstrates rapid aging and cannot be reactivated by pralidoxime. 7
Therapeutic implications: Once aging has occurred, the only treatment option is atropine to antagonize muscarinic effects, as oximes become completely ineffective at enzyme reactivation. 4, 7
Resistance Strategies
Mutant enzymes: Specific acetylcholinesterase mutations (Y337A/F338A) demonstrate enhanced reactivation rates and aging resistance when combined with oximes like HI-6, offering potential for catalytic bio-scavenging applications. 6
Enzyme recovery: In carbamate poisoning (which causes reversible inhibition), both blood acetylcholinesterase and butyrylcholinesterase activities gradually return to normal within 24 hours without aging complications. 8
Major Pitfalls to Avoid
Never delay atropine administration—prompt delivery improves survival in organophosphate poisoning (Class I, Level A). 4
Never use inadequate doses—titrate aggressively to defined atropinization endpoints, not standard bradycardia protocols. 4
Never assume atropine reverses paralysis—it only mitigates muscarinic effects and has no impact on nicotinic neuromuscular blockade. 4
Never withhold oximes when poison class is uncertain—empirical pralidoxime therapy is recommended despite aging concerns (Class IIa, Level A). 4
Never use succinylcholine or mivacurium for intubation in organophosphate-poisoned patients, as these are metabolized by cholinesterase (Class III). 4